Question 1

What is bciintel.com?

Accepted Answer

bciintel.com is the leading intelligence platform for the brain-computer interface industry — a Bloomberg Terminal-style dashboard covering funding rounds, device specifications, clinical trial data, market analysis, research papers, and breaking news across every major BCI company globally. Every figure ties back to a dated primary source — FDA and regulatory filings, clinical-trial registries, company announcements, and funding disclosures.

Question 2

Which BCI companies does bciintel.com track?

Accepted Answer

bciintel.com tracks all major brain-computer interface companies including Neuralink, Synchron, Precision Neuroscience, Paradromics, Blackrock Neurotech, BrainGate, EMOTIV, OpenBCI, Neurable, Kernel, Cognixion, NeuroPace, Medtronic, Abbott, Boston Scientific, and dozens more across the US, Europe, and Asia.

Question 3

How many humans have received BCI implants?

Accepted Answer

As of 2025, approximately 100 humans have received intracortical BCI implants. Neuralink's PRIME study has enrolled several participants, Synchron's Stentrode has been implanted in patients across the US and Australia, and Precision Neuroscience has performed multiple first-in-human demonstrations. The vast majority of BCI users use non-invasive EEG-based systems.

Question 4

What is the BCI market size?

Accepted Answer

The global brain-computer interface market was valued at approximately $2.8 billion in 2025 and is projected to reach $6–12 billion by 2030, representing a compound annual growth rate (CAGR) of 15–18%. Key growth drivers include ALS and spinal cord injury treatments, consumer neurotechnology, and expanding FDA regulatory approvals.

Question 5

What are the main types of brain-computer interfaces?

Accepted Answer

The main types of BCIs are: (1) Intracortical — electrodes implanted directly into brain tissue, highest signal quality, examples include Neuralink and BrainGate Utah arrays; (2) ECoG — electrocorticography electrodes on the brain surface, used in epilepsy monitoring; (3) EEG — non-invasive scalp electrodes, used in consumer headsets like EMOTIV and OpenBCI; (4) Endovascular — stent-based electrodes delivered through blood vessels, as in Synchron's Stentrode; (5) Peripheral nerve interfaces — implanted near peripheral nerves.

Question 6

What is Neuralink's current status?

Accepted Answer

Neuralink received FDA Investigational Device Exemption (IDE) approval in May 2023 and began the PRIME (Precise Robotically Implanted Brain-Computer Interface) study. As of 2025, multiple patients have been implanted with the N1 chip, including the first participant Noland Arbaugh, who demonstrated wireless computer control using only his thoughts. The device uses 1,024 electrodes on 64 threads inserted by the R1 surgical robot.

Question 7

What FDA approvals exist for BCIs?

Accepted Answer

FDA-approved BCI-adjacent devices include NeuroPace RNS (responsive neurostimulation for epilepsy, PMA approved 2013), Medtronic DBS systems (deep brain stimulation for Parkinson's and essential tremor), and Abbott's Proclaim system. Neuralink and Synchron both hold IDE (Investigational Device Exemption) status for research studies. The FDA has designated several BCI programs as Breakthrough Devices, accelerating review timelines.

Question 8

How often is data on bciintel.com updated?

Accepted Answer

bciintel.com's newsfeed aggregates primary sources — FDA and regulatory filings, clinical-trial registries, company announcements, and funding disclosures — and updates multiple times daily. The device database, funding tracker, clinical trial data, and company directory are updated regularly as new data becomes available.

254 people have received an investigational neural implant

Which trials are closest to an FDA decision

Clinical Pipeline

Capital Momentum

The field, by interface type

The Wire

Frequently asked